bull case, page-115

Company looks very interesting gang, just started doing some DD after seeing Tony Locantro call this his #1 stock pick for 2022. I had no idea about the prevalence of cholesterol lowering drugs. It's very encouraging that NYR's drug had outperformed Lipitor as a single agent in the same mouse model, with that awesome reduction when used in combination.

I am still early in my research so sorry if this has been discussed before, but would it be possible to patent the combination of Lipitor with NYR's drug to sell this combo as a single agent?

The user experience aspect of delivering this via a pill, versus frequent injections like Praluent, is also very important I think, both from the convenience but also price perspective. There are some medical treatments out there with low rates of continued usage despite efficacy, CPAP machines come to mind

Thanks to all holders and commenters contributing here, greatly helping with my research!